Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve.
J Adolesc Young Adult Oncol
; 13(3): 465-468, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38112555
ABSTRACT
Purpose:
To determine the impact of dose-dense chemotherapy administration on ovarian reserve in women undergoing treatment for breast cancer. Patients andMethods:
We conducted a retrospective cohort study of reproductive age women who underwent dose-dense chemotherapy regimens with doxorubicin hydrochloride and cyclophosphamide with or without paclitaxel for a new diagnosis of breast cancer. We compared pre- and post-treatment serum antimullerian hormone (AMH) levels and assessed changes in AMH over time.Results:
Fifty-seven patients met inclusion criteria. Median pre-treatment AMH was 2.9 ng/mL, whereas post-treatment AMH was 0.1 ng/mL, demonstrating a dramatic reduction in AMH levels after treatment with a dose-dense regimen. This change was independent of age and was sustained over 12 months from treatment completion.Conclusions:
Dose-dense chemotherapy regimens for breast cancer lead to marked and sustained decreases in AMH irrespective of patient age.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Hormônio Antimülleriano
/
Reserva Ovariana
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Adolesc Young Adult Oncol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos